Review

ConnectOne Bancorp, Inc. to Host 2022 Third Quarter Results Conference Call on October 27, 2022

Retrieved on: 
Thursday, October 13, 2022
GLOBE, Company, Webcast, Review, Nasdaq, Investor relations, Bank

ET on October 27, 2022, to review the Company's financial performance and operating results.

Key Points: 
  • ET on October 27, 2022, to review the Company's financial performance and operating results.
  • Chairman and Chief Executive Officer Frank Sorrentino III and Chief Financial Officer William S. Burns will host the call.
  • ET on Thursday, October 27, 2022 and ending on Thursday, November 3, 2022 by dialing 1-412-317-6671, access code 13733104.
  • ConnectOne Bancorp, Inc. is traded on the Nasdaq Global Market under the trading symbol "CNOB," and information about ConnectOne may be found at https://www.connectonebank.com .

Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference

Retrieved on: 
Thursday, October 13, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Institute of Liver and Biliary Sciences, Psoriasis, Colon, Communication, SEC, A3, Inflammation, Review, Woman, Conference, CANF, NYSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Drug development, Hepatocellular carcinoma, Erectile dysfunction, HCC, TASE, Cancer, Liver cancer, Technology, NASH, NYSE American, Food, Company, Prostate, Industry, Incidence, Liver, Melanoma, Forward-looking statement, Fatty liver disease, FDA, COVID-19, Pharmaceutical industry

Can-Fite is conducting a Phase IIb multicenter, randomized, double-blind, placebo-controlled study in subjects with biopsy-confirmed NASH.

Key Points: 
  • Can-Fite is conducting a Phase IIb multicenter, randomized, double-blind, placebo-controlled study in subjects with biopsy-confirmed NASH.
  • Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR).
  • Namodenoson is being evaluated for two indications, as a second line treatment for hepatocellular carcinoma in a pivotal Phase III study, and as a treatment for non-alcoholic steatohepatitis (NASH) in a Phase IIb study.
  • The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis.

Babylon Announces Third Quarter 2022 Financial Results Conference Call

Retrieved on: 
Thursday, October 13, 2022
Data Management, Practice Management, Technology, Managed Care, Health, Health Technology, Other Technology, Apps, Applications, Software, Artificial Intelligence, Mobile, Wireless, NHS, NYSE, Medicare, Health, Webcast, AI, Review, Population, Health insurance, Medicaid

Babylon (NYSE: BBLN) (Babylon or the Company) today announced it will host a conference call to review the Companys third quarter 2022 financial results in full on Thursday, November 10, 2022, at 8:00 AM Eastern Time.

Key Points: 
  • Babylon (NYSE: BBLN) (Babylon or the Company) today announced it will host a conference call to review the Companys third quarter 2022 financial results in full on Thursday, November 10, 2022, at 8:00 AM Eastern Time.
  • A press release announcing the third quarter results will be issued prior to the conference call on Thursday, November 10, 2022.
  • To participate in the live conference call and webcast, please dial (877) 407-7994 for U.S. participants, 0 800 756 3429 for U.K. participants, or +1 215-268-9868 for international participants.
  • In 2021 alone, Babylon helped a patient every 6 seconds, with approximately 5.2 million consultations and AI interactions.

Matador Resources Company Announces Date of Third Quarter 2022 Earnings Release

Retrieved on: 
Thursday, October 13, 2022
Oil, Gas, Energy, Eagle Ford, Dallas, NYSE, Bone Spring Formation, Central Time, Delaware Basin, Acquisition, Review, Natural gas, Bullfighter, Petroleum

Matador Resources Company (NYSE: MTDR) (Matador or the Company) today announced plans to release third quarter 2022 operational and financial results after the close of trading on Tuesday, October 25, 2022.

Key Points: 
  • Matador Resources Company (NYSE: MTDR) (Matador or the Company) today announced plans to release third quarter 2022 operational and financial results after the close of trading on Tuesday, October 25, 2022.
  • Management will also host a live conference call on Wednesday, October 26, 2022 at 9:00 a.m. Central Time to review third quarter 2022 financial results and operational highlights.
  • To access the live conference call by phone, you can use the following link https://register.vevent.com/register/BIfe50f2205466458585c54e9b056b55c3 and you will be provided with dial in details.
  • To avoid delays, it is recommended that participants dial into the conference call fifteen minutes ahead of the scheduled start time.

Philips expands rollout of its ClarifEye augmented reality surgical navigation solution to Japan

Retrieved on: 
Thursday, October 13, 2022
The Spine Journal, 3D CT, Observation, Lumbar spinal stenosis, Literature, AEX, Spine, Trauma, Journal, Scientific Reports, Philips, Surgeon, International University, Scoliosis, Population, EOC, AR, NYSE, 3D, World Neurosurgery, Spinal disease, Orthopedic surgery, Department, Skin, Hospital Sant Joan de Déu Barcelona, International University of Health and Welfare, Journal of Orthopaedic Science, Risk, 2D, Bleeding, European Spine Journal, PHG, Augmented reality, ISSN, Technology, Live Phish Volume 18, Pain, Ageing, Spinal stenosis, Review, Hybrid, Patient, Hospital, MD, Doctor of Philosophy, Prevalence, Intra, Medical device, Medical imaging

Philips augmented reality surgical navigation solution - ClarifEye - combines 2D and 3D visualizations at low X-ray dose with 3D AR navigation into one system.

Key Points: 
  • Philips augmented reality surgical navigation solution - ClarifEye - combines 2D and 3D visualizations at low X-ray dose with 3D AR navigation into one system.
  • Compared to existing navigation systems, ClarifEye has no reference frame-related errors, and its wonderful that it achieves real time imaging with pedicle segmentation.
  • [4] Elmi-Terander A at el, Augmented reality navigation with intraoperative 3D imaging vs fluoroscopy-assisted free-hand surgery for spine fixation surgery, a matched-control study, Nature Sci.
  • accuracy results from a multicenter, prospective clinical study using a skin markerbased optical navigation system, European Spine Journal, Sept 2022.

AMAZFIT LAUNCHES THE AMAZFIT FALCON, A PREMIUM MULTI-SPORT GPS WATCH

Retrieved on: 
Thursday, October 13, 2022
Strava, Google Fit, Titanium, AliExpress, Wrist, Heart rate, Red Dot, Kiteboarding, EMEA, Review, Golf swing, NYSE, Washington Apple Health, APAC, Music, Multimedia, GPS, Sport, Goal, Friends, Exercise, Health, Zepp, Step Up Your Game, Eve Stewart, Athlete, TC4, Triathlon, USD, Satellite navigation device, Mobile phone, Amazfit, Amazon

CUPERTINO, Calif., Oct. 13, 2022 /PRNewswire/ --Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), a health technology company, has introduced its first ever premium multi-sport GPS watch, the Amazfit Falcon.

Key Points: 
  • CUPERTINO, Calif., Oct. 13, 2022 /PRNewswire/ --Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), a health technology company, has introduced its first ever premium multi-sport GPS watch, the Amazfit Falcon.
  • Crafted with a high-end titanium unibody and sapphire crystal glass screen, and featuring strong and accurate GPS tracking, advanced training support, and 20 ATM water-resistance, the Amazfit Falcon is built to break limits.
  • As the ultimate workout partner, the Amazfit Falcon is just as suited to outdoor sports as indoor activities.
  • With outstanding craftsmanship, Amazfit smartwatches have won many design awards, including the iF Design Award and the Red Dot Design Award.

AMAZFIT LAUNCHES THE AMAZFIT FALCON, A PREMIUM MULTI-SPORT GPS WATCH

Retrieved on: 
Thursday, October 13, 2022
Strava, Google Fit, Titanium, AliExpress, Wrist, Heart rate, Red Dot, Kiteboarding, EMEA, Review, Golf swing, NYSE, Washington Apple Health, APAC, Music, Multimedia, GPS, Sport, Goal, Friends, Exercise, Health, Zepp, Step Up Your Game, Eve Stewart, Athlete, TC4, Triathlon, USD, Satellite navigation device, Mobile phone, Amazfit, Amazon

CUPERTINO, Calif., Oct. 13, 2022 /PRNewswire/ --Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), a health technology company, has introduced its first ever premium multi-sport GPS watch, the Amazfit Falcon.

Key Points: 
  • CUPERTINO, Calif., Oct. 13, 2022 /PRNewswire/ --Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), a health technology company, has introduced its first ever premium multi-sport GPS watch, the Amazfit Falcon.
  • Crafted with a high-end titanium unibody and sapphire crystal glass screen, and featuring strong and accurate GPS tracking, advanced training support, and 20 ATM water-resistance, the Amazfit Falcon is built to break limits.
  • As the ultimate workout partner, the Amazfit Falcon is just as suited to outdoor sports as indoor activities.
  • With outstanding craftsmanship, Amazfit smartwatches have won many design awards, including the iF Design Award and the Red Dot Design Award.

IRRAS Announces Participation and Data Presentation at the 22nd European Congress of Neurosurgery

Retrieved on: 
Thursday, October 13, 2022
Congress, CET, Jean-Louis Vincent, Review, ICH, Patient, Hospital, Aneurysm, COVID-19, IVH, Hummingbird, Cerebrospinal fluid, Association, ARCH, Intraventricular hemorrhage, Intracerebral hemorrhage, Neurological Society of India, Clinical trial, European Association of Urology, Nasdaq Stockholm, EANS, Medical device, Nightclub, Pharmaceutical industry, Neurosurgery, European

The 22nd European Congress of Neurosurgery will take place in Belgrade, Serbia, on October 16-20, 2022.

Key Points: 
  • The 22nd European Congress of Neurosurgery will take place in Belgrade, Serbia, on October 16-20, 2022.
  • Dr. Rezai Jahromi will also lead a live IRRAflow educational session on Tuesday, October 18th, at 1000 CET within the IRRAS booth in the Congress' Exhibit Hall.
  • STOCKHOLM, Oct. 13, 2022 /PRNewswire/ --IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced it will be exhibiting at EANS 2022, the 22nd European Congress of Neurosurgery, hosted by the European Association of Neurological Societies.
  • Attendees of EANS 2022 are encouraged to learn more about IRRAS' products, including its IRRAflow Active Fluid Exchange system, by visiting IRRAS' booth #10.

IRRAS Announces Participation and Data Presentation at the 22nd European Congress of Neurosurgery

Retrieved on: 
Thursday, October 13, 2022
Congress, CET, Jean-Louis Vincent, Review, ICH, Patient, Hospital, Aneurysm, COVID-19, IVH, Hummingbird, Cerebrospinal fluid, Association, ARCH, Intraventricular hemorrhage, Intracerebral hemorrhage, Neurological Society of India, Clinical trial, European Association of Urology, Nasdaq Stockholm, EANS, Medical device, Nightclub, Pharmaceutical industry, Neurosurgery, European

The 22nd European Congress of Neurosurgery will take place in Belgrade, Serbia, on October 16-20, 2022.

Key Points: 
  • The 22nd European Congress of Neurosurgery will take place in Belgrade, Serbia, on October 16-20, 2022.
  • Dr. Rezai Jahromi will also lead a live IRRAflow educational session on Tuesday, October 18th, at 1000 CET within the IRRAS booth in the Congress' Exhibit Hall.
  • STOCKHOLM, Oct. 13, 2022 /PRNewswire/ --IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced it will be exhibiting at EANS 2022, the 22nd European Congress of Neurosurgery, hosted by the European Association of Neurological Societies.
  • Attendees of EANS 2022 are encouraged to learn more about IRRAS' products, including its IRRAflow Active Fluid Exchange system, by visiting IRRAS' booth #10.

Third quarter 2022 operational review

Retrieved on: 
Thursday, October 13, 2022
News, Molybdenum, ROM, Review, Total, TSX, AIM, Gold, Horizontal, Company, SRB, Matilda, Mining, Silver, Palladium, Uranium, Lithium, Zonta, Palito, Coringa

Third Quarter gold production totalled 8,542 ounces recovered, compared to 8,418 ounces in the second quarter.

Key Points: 
  • Third Quarter gold production totalled 8,542 ounces recovered, compared to 8,418 ounces in the second quarter.
  • Significant channel samples (see news release dated 17 August 2022) included:
    The third quarter saw 2,600 tonnes of higher grade Coringa development ore transported to Palito, contributing 570 ounces of gold production for the quarter.
  • Another strong quarter for Serabi, with 8,542 ounces produced, which is the best quarter this year meaning we are on track to now exceed our revised 2022 guidance of 30,000 ounces.
  • Total production for the third quarter of 2022 was 8,542 ounces, (Q1 2022: 7,062 ounces, Q2 2022: 8,414 ounces).